Development of lipopeptides for inhibiting 20S proteasomes

被引:17
作者
Basse, Nicolas
David, Papapostolou
Pagano, Maurice
Reboud-Ravaux, Michele
Bernard, Elise
Felten, Anne-Sophie
Vanderesse, Rgis
机构
[1] Univ Paris 06, CNRS, FRE2852, Lab Enzymol Mol & Fonct,Inst Jacques Monod, F-75251 Paris 05, France
[2] CNRS, INPL, UMR, Lab Chim Phys Macromol, F-54001 Nancy, France
关键词
proteasome; inhibitors; lipopeptides;
D O I
10.1016/j.bmcl.2006.03.033
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Proteasomes are responsible for the cytoplasmic turnover of the vast majority of proteins including regulatory proteins. We have synthesized lipopeptides a new class of non-covalent inhibitors of the 20S proteasome and assayed their inhibitory capacities. Their ability to inhibit at micromolar concentrations chymotrypsin-like and post-acid activities depends on peptide length (3 or 6 amino acids), sequence (presence of a positively or negatively charged amino acid), and alkyl chain length (C6-C18). These structural features could be varied to selectively inhibit one or more of the three proteasome activities. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3277 / 3281
页数:5
相关论文
共 20 条
[1]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[2]  
ADAMS J, 2003, NAT REV CANCER, V5, P417
[3]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[4]   Structure and functions of the 20S and 26S proteasomes [J].
Coux, O ;
Tanaka, K ;
Goldberg, AL .
ANNUAL REVIEW OF BIOCHEMISTRY, 1996, 65 :801-847
[5]   Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation [J].
Craiu, A ;
Gaczynska, M ;
Akopian, T ;
Gramm, CF ;
Fenteany, G ;
Goldberg, AL ;
Rock, KL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (20) :13437-13445
[6]   Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design [J].
Furet, P ;
Imbach, P ;
Noorani, M ;
Koeppler, J ;
Laumen, K ;
Lang, M ;
Guagnano, V ;
Fuerst, P ;
Roesel, J ;
Zimmermann, J ;
García- Echeverría, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (20) :4810-4813
[7]   Not just research tools - proteasome inhibitors offer therapeutic promise [J].
Goldberg, AL ;
Rock, K .
NATURE MEDICINE, 2002, 8 (04) :338-340
[8]   The catalytic sites of 20S proteasomes and their role in subunit maturation:: A mutational and crystallographic study [J].
Groll, M ;
Heinemeyer, W ;
Jäger, S ;
Ullrich, T ;
Bochtler, M ;
Wolf, DH ;
Huber, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :10976-10983
[9]   Substrate access and processing by the 20S proteasome core particle [J].
Groll, M ;
Huber, R .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (05) :606-616
[10]   Crystal structure of the 20 S proteasome: TMC-95A complex: A non-covalent proteasome inhibitor [J].
Groll, M ;
Koguchi, Y ;
Huber, R ;
Kohno, J .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 311 (03) :543-548